New Drugs and Clinical Trials · global
Retatrutide outperforms Ozempic in blood sugar reduction and weight loss in Phase 3 trial, with higher discontinuation rates
In a head-to-head trial announced by Eli Lilly, retatrutide helped patients with type 2 diabetes lose an average of about one-fifth of their body weight over 80 weeks. The findings add clinical evidence for the triple-receptor drug, but the method used to estimate efficacy, tolerability, and full data yet to be released also affect how the results should be interpreted.
For patients with type 2 diabetes who need to manage both blood sugar and weight, a direct comparison offers more convincing evidence of whether a new drug can outperform existing treatment than impressive numbers from separate studies. On October 28, Eli Lilly announced preliminary results from the Phase 3 TRANSCEND-T2D-2 trial: the investigational drug retatrutide produced greater reductions in blood sugar and body weight than Ozempic 2 mg after 80 weeks, but a higher proportion of patients discontinued treatment because of adverse events. Full results await presentation at a medical conference and peer review.
The randomized, open-label trial enrolled 1,298 adults whose blood sugar remained inadequately controlled despite taking metformin, with some also taking an SGLT2 inhibitor. Participants were assigned in a 2:2:1 ratio to retatrutide 9 mg, retatrutide 12 mg, or Ozempic 2 mg, all administered by injection once weekly. Open-label means that participants and researchers knew which drug was being used; the comparator was the highest approved dose of Ozempic for treating diabetes.
According to the efficacy estimates released by the company, mean glycated hemoglobin (HbA1c) fell by 2.2 percentage points in both retatrutide dose groups, compared with 1.8 percentage points in the Ozempic group. HbA1c reflects blood sugar control over a period of time; participants had a mean baseline value of 8.3%. The difference in weight loss was larger: mean body weight fell by 19.5% and 20.9% in the 9 mg and 12 mg groups, respectively, equivalent to approximately 20.1 and 21.5 kg. The Ozempic group lost 9.4%, or approximately 9.5 kg.
The claim of “more than twice the weight loss” still needs to be read alongside the analytical method. Lilly reported an efficacy estimand, which estimates what the effects would be if all randomized participants continued receiving the study treatment without prolonged use of additional blood sugar-lowering medication. These figures therefore cannot be treated directly as average results that fully account for treatment discontinuation and additional therapy, nor can they simply be applied to people without diabetes seeking weight loss.
Tolerability is another consideration. Data compiled by BioPharm International show that 4.8% and 7.9% of participants in the retatrutide 9 mg and 12 mg groups, respectively, discontinued treatment because of adverse events, compared with 2.7% in the Ozempic group. Common adverse events were primarily gastrointestinal symptoms, including diarrhea, nausea, and vomiting; Lilly said most were mild to moderate. Greater average weight loss must be weighed alongside patients’ ability to remain on treatment.
Retatrutide is designed as a single molecule that activates three receptors: GLP-1, GIP, and glucagon. Semaglutide, the active ingredient in Ozempic, acts on the GLP-1 receptor. ABC News also described the drug in terms of its once-weekly injection and activity at three receptors, but the efficacy figures in that report and in BioPharm International’s coverage both came from Lilly’s announcement, rather than a separate independent validation.
This trial provides evidence for the triple-receptor strategy in a direct comparison with an existing drug, but it does not yet offer a complete picture of clinical benefit. Improvements in blood sugar and weight cannot be equated directly with proven reductions in heart attacks, worsening kidney disease, or death. As of this announcement, retatrutide had not been approved by any regulatory authority. The forthcoming full paper will allow the medical community to examine treatment discontinuation, missing data, and safety more closely, and assess whether the efficacy advantage can translate into long-term treatment value.